Use the hyperlinks, where available to access additional clinical trial information.
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, MÃ¼nster (BFM) Study Group
Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)
Other Non-Commercial Sponsor
Charite University, Berlin, Germany
This is a randomised, open-label trial with two arms. Participants in Arm A will receive Backbone ALL R3. Participants in Arm B will receive Backbone ALL Re + Bortezomib. Bortezomib will be administered at 1.3mg/m2 as intravenous bolus or subcutaneously on days 1 and 4 of weeks 1 and 3.